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Abstract
Background: The treatment of ulcerative colitis (UC) can place a substantial financial burden on healthcare systems.
The anti-inflammatory compound 5-aminosalicylic acid (5-ASA; mesalazine) is the recommended first-line treatment
for patients with UC. In this analysis, the incremental cost effectiveness ratio (ICER) of two oral formulations of 5-ASA
(Mezavant® and Asacol®) is examined in the treatment of patients with mild-to-moderate, active UC in Germany.
Methods: A Markov cohort model was developed to assess the cost effectiveness of Mezavant compared with Asacol
over a 5-year period in the German Statutory Health Insurance (SHI). Drug pricing details for 2009 were applied
throughout the model, and overall resource use was determined and also fitted to 2009 from published results of a
large cross sectional study of German SHI patients. Cost per quality adjusted life year (QALY) was the primary endpoint
for this study. Remission rates were obtained using data from a randomised, phase III trial of Mezavant with an active
Asacol reference arm and a long-term, open label, safety and tolerability trial of Mezavant. Uncertainty in the study
model was assessed using one-way and probabilistic sensitivity analyses applying a Monte Carlo simulation.
Results: Over a 5-year period, healthcare costs for patients receiving Mezavant were 624 Euro lower than for patients
receiving Asacol. Additionally, patients receiving Mezavant gained 0.011 QALYs or 18 more days in remission
compared with Asacol. One-way sensitivity analyses suggest that these results are driven by both differences in the
acquisition cost between mesalazine formulations and differences in treatment efficacy. Furthermore, sensitivity
analyses suggest a probability of 76% for cost savings and higher QALYs with Mezavant compared with Asacol. If
adherence and its influence on the remission rates and the risk of developing colorectal cancer were included in the
model, the results might have even been more favorable to Mezavant due to its once daily dosing regimen.
Conclusions: This model suggests that patients treated with Mezavant may achieve increased time in remission
and higher QALYs, with lower direct costs to the SHI when compared with Asacol. Mezavant may therefore be a
suitable first-line option for the induction and maintenance of remission in UC.
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Background
Ulcerative colitis (UC) is a relapsing non-transmural
inflammatory bowel disease that is restricted to the
colon. Patients typically have bloody diarrhea (often
nocturnal and postprandial), passage of pus, mucus, or
both, and abdominal cramping during bowel movements
[1]. This chronic symptomatic morbidity is associated
with impairment of health-related quality of life, higher
unemployment, and productivity loss [2].
In Germany, there are about 160,000 prevalent UC-
cases [3]. The incidence of UC amounts to around 6/
100,000 cases a year [4-6]. The treatment of these
patients during the different disease states can place a
substantial financial burden on the healthcare system.
For example, the German Federal Statistical Office esti-
mated health care costs due to UC at 233 million Euro in
2006 [7]. Hence, analyses which compare cost and benefit
of different health care interventions become more and
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more important for the German health care sector in
order to identify cost effective treatment options.
In Germany, several medications are approved for the
treatment of UC-patients during remission and active
states. Today, the recommended first-line treatments for
mild to moderate UC are anti-inflammatory 5-aminosa-
licylic acid (5-ASA) preparations containing sulfasalazine,
mesalazine or olsalazine. Since February 2008, a new
mesalazine preparation (Mezavant®, Shire Pharmaceuticals
Inc.)-utilizing MMX® technology (trademark of Cosmo
Technologies Ltd, Wicklow, Ireland)-is available in
Germany. Mezavant is indicated for the induction of clini-
cal and endoscopic remission in patients with mild-to-
moderate, active UC as well as for the maintenance of
remission. The delivery system of Mezavant uses lipophilic
and hydrophilic matrices enclosed within a gastro-resis-
tant, pH-dependent coating in order to facilitate prolonged
exposure of the colonic mucosa to mesalazine. Mezavant
is administered only once a day with tablets containing
1,200 mg of mesalazine; this differs from some other oral
mesalazines, e.g. Asacol®, which is available in 400 mg
tablets and administered two or three times daily. Asacol
(Procter & Gamble, USA) is also indicated for mild-to-
moderate acute exacerbations of UC and the maintenance
of remission of UC. The simple dosing regimen of Meza-
vant with only once daily intake of 2 to 4 tablets may have
potential benefits in comparison to other treatment
options by improving patient adherence, which in turn
may affect the recurrence of disease exacerbations and
reduce resource utilization such as surgery and hospitali-
zation and associated costs.
However, as stated above, the cost effectiveness of new
treatment options becomes more and more important in
the German setting. Therefore, the aim of this study is to
examine the cost effectiveness of Mezavant in compari-
son to Asacol in the treatment for induction and mainte-
nance of remission in patients with mild-to-moderate UC
in Germany.
Methods
To assess the cost effectiveness of Mezavant compared
with Asacol, a Markov cohort model was developed. The
primary endpoint in this analysis was incremental cost
per additional quality-adjusted life year (QALY) and the
evaluation was conducted from the perspective of the
Statutory Health Insurance (SHI) in Germany. The struc-
ture of the model, the input data (transitions probabil-
ities, utilities and costs) as well as the analysis procedure
is described in detail below.
Structure of the markov model
The model [8] simulates the dynamic treatment path of
an UC-patient. The modeled treatment period in the
base case was five years, divided into 8-week cycles
which match the reporting period of the clinical trials
[9,10]. In total, the model includes eight possible health
states.
In first line treatment, newly diagnosed or relapsing
patients (relapsed ≤ 6 weeks prior to baseline) with active,
mild-moderate UC receive either Mezavant of Asacol,
each at 2,400 mg a day. Patients who do not respond
to the first line treatment receive an increased dosage
(4,800 mg/day) of Mezavant or Asacol, respectively. In
case the increased dosage does not lead to a remission,
oral corticosteriods are added to the mesalazine treatment
(second line treatment). In case the second line therapy
also fails, it is assumed that patients need hospitalization
(without surgery) to receive immunosuppressants and/or
intravenous steroids [8]. Hospitalization including surgery
is necessary if the treatment still does not lead to a remis-
sion for patients. Patients, who have undergone surgery,
enter the post-surgery state. It is assumed that these
patients are not in an active state anymore. Remission is
defined as a status in which patients have no or reduced
UC symptoms, which also might be entered from all
health states except surgery, post-surgery and death. The
death state can be entered from any status either due to
all other cause mortality or surgery. The structure of the
cost effectiveness model is presented in Figure 1.
Transition probabilities
Remission rates were obtained using data from two clin-
ical trials: one phase III, randomized, placebo-controlled
study [9] and one open-label extension study [10] which
assessed the long-term safety, tolerability and mainte-
nance of remission. The efficacy of Mezavant was also
assessed in another clinical trial (Lichtenstein et al.
(2007) [11]). However, since this trial did not include an
active comparator reference arm, the results of the
study were not eligible for this kind of comparing cost
effectiveness analysis.
Figure 1 Structural diagram of the cost effectiveness model.
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Within the phase III study [9], UC-patients were trea-
ted with a once daily active dose of 2,400 mg Mezavant,
2,400 mg Asacol (divided into three doses of 800 mg
each) or placebo (administered as double-dummy) for
eight weeks. (Furthermore, in one treatment arm
patients were initiated on treatment with a higher dose
of Mezavant (4,800 mg) in the trial; however, the results
of this arm were not included in the model, since no
comparable dosing regimen for Asacol is available.) The
remission rates within this time period were 40.5% for
patients treated with 2,400 mg Mezavant, 32.6% for
patients treated with Asacol and 22.1% for placebo.
Remission was defined as a modified UC-DAI-score
[made up of scores for rectal bleeding, stool frequency,
physician global assessment, and sigmoidoscopic muco-
sal appearance] of ≤ 1 with a score of 0 for rectal bleed-
ing and stool frequency as well as at least a 1-point
reduction from baseline in the sigmoidoscopy score and
no friability of the mucosa [9]. Patients (Asacol-and
Mezavant-patients) who did not achieve remission dur-
ing the eight weeks were enrolled in the open-label
extension study [10] and received an increased dose of
4,800 mg/day Mezavant. Patients who had initially
received Mezavant in the phase III trial achieved a
remission rate of 61.5% in the open-label extension;
Asacol-patients from the original pivotal trial, who were
treated with an increased dose of Mezavant in the open-
label extension study, achieved a remission rate of
61.0%. No trial data was available giving information on
the remission rate of Asacol-patients who received an
increased dose of Asacol. Therefore, the authors made a
conservative assumption against Mezavant and supposed
that the remission rate of Asacol-patients receiving an
increased dose of Asacol is equal to the remission of
Asacol-patients who received an increased dosage of
Mezavant in the extension study (= 61.0%).
Besides the information from these two trials, further
remission rates and transition probabilities were neces-
sary for the setup of the cost effectiveness model.
Remission rates from second-line treatment with corti-
costeroids (prednisolone) were reported by Lennard-
Jones et al. with 68% [12]. As stated above, in the model
it is assumed that those patients who do not achieve
remission in second line treatment require hospitaliza-
tion (health state: “Active UC: mesalazine failure”). The
transition probability to the health state “Surgery” was
taken from the official hospital statistics of the German
Federal Statistical Office (10.9% of all hospitalized UC-
patients require surgery) [13].
Furthermore, to determine an eligible probability of
remaining in the remission state, the results of the stu-
dies of Prantera et al. [14] as well as Langholz et al. [15]
were combined. Prantera et al. conducted a clinical
study in Italy, Poland and Ukraine by comparing the
maintenance of UC-patients in remission taking either
Mezavant or Asacol over a period of one year. Accord-
ing to the results, after 12 months, 62.2% of the Meza-
vant-patients and 51.5% of the Asacol-patients (p <
0.05) were still in remission (based on the UC-DAI and
patient diaries which document a worsening in stool fre-
quency and increased rectal bleeding). If only the UC-
DAI data was taken into account (without patient diary),
the remission rates were 68.0 and 65.9%, respectively
(p = 0.69). For the base case, however, the above men-
tioned rates which include information from patient dia-
ries are applied, since regulatory guidelines stress the
importance of obtaining direct patient input [e.g. [16]].
However, the other remission rates are applied in a sen-
sitivity analysis. Within the model, the figures (62.2 and
51.5%) were then extrapolated to the base case study
period of five years by applying findings from Langholz
et al. [15]. The authors found out that the probability of
experiencing a relapse diminishes by 1% each additional
year spent in remission.
Age-specific overall cause mortality data (2005/2007)
was taken from the German Federal Statistical Office [17].
Patients in the model started with an average age of 43.2
years and thus reflecting the underlying data from the
clinical trial [9]. For patients, who undergo surgery, it was
anticipated, that they have a higher mortality rate. How-
ever, for Germany no sufficient data regarding the higher
mortality rate of UC-patients due to surgery could be
identified, which led to the inclusion of UK-specific data.
The UK Inflammatory Bowel Disease Audit [18] reports
that of all UC inpatient admissions (2,767 inpatient admis-
sions) 45 patients died. Of those, 25 deaths were directly
related to UC including 15 that occurred in patients that
underwent surgery (715 surgeries). This results in a mor-
tality rate of 2.1% (15/715) directly due to surgery.
An overview and summary of the presented transition
probabilities is given in table 1.
Utility data
Utility data for UC-patients was derived from two stu-
dies [19,20] in which utility scores were obtained via a
Time Trade Off approach and the EQ-5D from a sample
of 151 patients with UC. Simultaneously, the researchers
also collected data on the clinical severity of the disease.
The results of these studies were adapted to fit the spe-
cified model health states (see table 2)
Resource use and cost data
Resource use and costs were determined from published
results of a large cross sectional study of patients with
UC in Germany [21]. Within this study, 519 patients with
UC from 24 ambulatory gastroenterological specialists’
practices and two hospitals were enrolled. For these
patients, outpatient and inpatient visits, outpatient
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procedures as well as prescribed medications were
recorded. The resource use was evaluated from the per-
spective of the Statutory Health Insurance (SHI) in Ger-
many, taking also into consideration patient co-payments
as well as discounts given by the manufacturer and phar-
macies as required by legal obligations in Germany. For
this, the current German guideline [22] for the identifica-
tion and valuation of resource usage was applied to eval-
uate the costs from the perspective of the SHI. The price
year which was used in the UC-study [21] was 2007. For
this present cost effectiveness analysis, the resource use
collected in the cross sectional study was re-fitted to
2009 from the perspective of the German SHI on the
basis of the current reimbursement practice. In the fol-
lowing, costs are described in detail:
Medication costs
According to the German guideline [22], the prices for
medications are generally based on the largest available
pack size. Furthermore, since prices of medications vary
throughout a year, the costs from the middle of the year
(July 1st, 2009) should be used for health economic evalua-
tions. In Germany, mesalazine is part of the reference price
system (Festbetrag) which defines costs per mg depending
on pack size. In addition, since costs have to be valued
from the perspective of the SHI, co-payments as well as
manufacturer and pharmacy discounts need to be sub-
tracted from the reference price. Taking all these require-
ments into consideration, the costs for a Mezavant (1,200
mg) tablet were 1.13 Euro and the costs for an Asacol (400
mg) tablet are 0.44 Euro. Costs for an oral corticosteroid
(prednisolone), which is applied daily in the 2nd line treat-
ment in addition to mesalazine, are 0.25 Euro per 40 mg
[23]. Since clinical guidelines suggest to reduce the dosage
gradually within the 8-week-cycle, the prednisolone dose is
reduced each week by 5 mg (after starting at 40 mg).
Accordingly, the costs are reduced during the cycle.
Table 1 Overview over the transition probabilities
To ... (M: Mezavant cohort; A: Asacol cohort)
From ... 1st line 1st line increased
dosage
2nd
line
Failure/
relapse
Surgery Post
surgery
Remission Death
Active UC: 1st line M: 59.5%
A: 67.4%
M: 40.5%
A: 32.6%
0.0%**
Active UC: 1st line increased
dosage
M:
38.5%
A: 39.0%
M: 61.5%
A: 60.0%
0.0%**
Active UC: 2nd line M: 32.0%
A: 32.0%
M: 68.0%
A: 68.0%
0.0%**
Active UC: Failure/relapse M:
25.8%
A: 25.8%
M: 74.2%
A: 74.2%
0.0%**
Surgery M: 97.9%
A: 97.9%
M: 2.1%
A: 2.1%
Post surgery M: 100.0%
A: 100.0%
0.0%**
Remission M: 6.5%
*
A: 9.2%*
M: 93.5%
A: 90.8%
0.0%**
Death M:
100.0%
A: 100.0%
* This figure decreases as time spent in remission decreases the risk of active episodes [14,15].
** The overall cause mortality data [16] (dependent on the age cohort) is below 0.05% and is therefore displayed in the table as 0.0%.
Table 2 Utility values for modeled health states [19,20]
Health State Utility (SD) Disease severity/Assumptions
Active UC: 1st line 0.589 (0.269) Mild-to-moderate active disease (SCAI = 4-10)
Active UC: 1st line increased dosage 0.589 (0.269) Mild-to-moderate active disease (SCAI = 4-10)
Active UC: 2nd line 0.589 (0.269) Mild-to-moderate active disease (SCAI = 4-10)
Active UC: Failure/relapse 0.317 (0.315) Severely active disease (SCAI > 10)
Surgery 0.317 (0.315) Assumption: utility is equal to the utility of patients with relapse
Post surgery 0.845 (0.195) Assumption: utility is equal to the utility of patients in remission
Remission 0.845 (0.195) Patients in remission (SCAI < 4)
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Outpatient costs
In Germany (since 2009) physicians are reimbursed via
lump sum payments per quarter, independently from the
number of visits of a patient per quarter. According to
the official German Uniform Valuation Scheme (EBM),
gastroenterologists received 18.90 Euro per patient per
quarter (not including special procedures) in 2009. It is
assumed that this lump sum payment occurs once a
quarter for patients in an active disease state. In the pre-
sent model, the cycle length with eight weeks is less than
a quarter. To follow a conservative approach, these costs
were fit to the cycle length (18.90 · 8/13 = 11.63 Euro).
Furthermore, the above mentioned German UC-study
[21] documented the type and amount of outpatient pro-
cedures for active UC-patients (e.g. colonoscopy, ultraso-
nography). This resource use was revalued on the basis
of the price year 2009. According to the calculations, a
UC-patient in an active disease status caused outpatient
procedures costs of 115.63 Euro within a six month per-
iod. To fit this data to the cycle length of eight weeks,
these costs were divided by 26 and multiplied with eight
weeks (115.63 · 8/26 = 35.58 Euro). In total, during the
period of eight weeks, an UC-patient in an active disease
status caused outpatient costs of 47.21 Euro from the
perspective of the SHI in Germany. We assumed that no
outpatient costs were caused by patients in the remission,
post-surgery, inpatient or surgery model state.
Inpatient costs
In Germany, inpatient stays are reimbursed via lump sums
(diagnosis related groups, DRG) as well. The DRGs which
were chosen for this analysis were obtained from the Ger-
man cost study [21] and fitted to 2009. Hence, an inpatient
stay without surgery was reimbursed with 1,584.27 Euro,
an inpatient stay including surgery with 3,812.55 Euro
from the perspective of German SHI (again also taking co-
payments by patients into account) [24].
Analysis
The outputs of the model are expressed as an incremental
cost effectiveness ratio (ICER), presenting incremental
costs per additional quality adjusted life year (QALY)
gained. All costs and QALYs are discounted at an annual
rate of 5% according to the current German Recommen-
dations on Health Economic Evaluation (Hannover Con-
sensus) [25]. Uncertainty in the model was assessed using
one-way and probabilistic sensitivity analysis (PSA). The
PSA was performed with 10,000 Monte Carlo simulations,
drawing random values for health state costs, utilities and
remission rates, with the observed parameter distribution
in the data source.
Results
On the basis of this deterministic approach (using the
mean parameter values) overall healthcare costs for a
patient receiving Mezavant were 624 Euro lower than
for a patient receiving Asacol over a 5-year time period.
Additionally, patients receiving Mezavant gained slightly
more QALYs (0.011) in comparison to patients who
received Asacol. The results lead to a negative ICER
which means that Mezavant is dominant in comparison
to Asacol due to lower costs and also higher benefits in
terms of QALYs. The results from the probabilistic sen-
sitivity analysis confirm the dominance of Mezavant in
comparison to Asacol. Detailed results are shown in
table 3.
The primary outcome measure of this cost effectiveness
analysis was the benefit in terms of a QALY. However, in
addition, other measures of effectiveness were also evalu-
ated. Results were consistent with all other analyses. For
instance, patients receiving Mezavant spent 18 more days
in remission in comparison to Asacol and had 0.03 inpati-
ent episodes as well as 0.002 surgeries less in the time
frame of five years as set in the base case of the analysis.
The analysis was also repeated with a lifelong time hori-
zon. According to the calculations, a treatment with Meza-
vant leads to 1,992 Euro less in costs than Asacol per
patient. Furthermore, patients incrementally gain 0.028
QALYs in comparison to Asacol. In total, the lifelong
model also results in a dominant alternative with
Mezavant.
One-way sensitivity analyses suggest that these find-
ings are driven by differences in the acquisition cost of
mesalazine formulations as well as the efficacy of the
respective treatments. However, the different long-term
remission rates presented by Prantera [14] do not have
a major impact on the results. Even if the same long-
term efficacy was applied for both treatment arms (e.g.
68%), Mezavant remains dominant over Asacol.
The PSA indicates a probability of 76% for cost savings
and higher QALYs with Mezavant compared with Asacol.
A scatter plot of the analysis is illustrated in Figure 2.
Discussion
This study has some limitations which will be addressed
in the following.
Within this study, we extrapolated 16-weeks-clinical trial
data to a five year time horizon which is associated with
some uncertainties. Furthermore, the study from Prantera
et al. [14], which was used for the long-term remission
maintenance rates, only lasts for one year. However, to
our knowledge, no other data exists, which gives informa-
tion about the long-term effects of Mezavant versus
Asacol treatment. Initial remission rates of Mezavant and
Asacol were taken from a single study [9] to ensure inter-
nal validity (e.g. consistent endpoints or homogeneity of
included patients). Nevertheless, other clinical trials
(Schroeder et al. [26]; Sninsky et al. [27]) are documented
which also investigated the efficacy of Asacol. However,
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the reported remission rates are in line with the findings of
the study of Kamm et al. [9], although other clinical end-
points were set and a six-week-period was chosen as a
trial length. All in all, these studies support the conserva-
tive assumption included in the present study regarding
the inclusion of a remission rate of 61.0% for Asacol-
patients receiving an increased dose of mesalazine.
It also might have been reasonable from the clinical
trial data to assume an even lower remission rate due to
the fact that patients who initially received Asacol and
did not achieve a remission in the first eight weeks were
henceforth treated with an increased dose of Mezavant.
Since the remission rate of Mezavant in the first eight
weeks was higher than the rate of Asacol (40.5% versus
32.6%), it could have been also assumed that an
increased dosage of Asacol would not have had the
same positive effect as an increased dose of Mezavant.
Hence, an alteration of the model inputs reflecting the
other clinical studies for Asacol might have been even
more favorable to Mezavant.
Within the evaluation, it was assumed that patients are
fully adherent. Higher adherence is associated with a
reduced probability of relapses as many published find-
ings suggest [28,29]. One aspect which influences adher-
ence is the frequency of dosing. For instance, Kane et al.
[28] reports adherence rates of maintenance therapy in
UC-patients by dosing regimen: 39% for twice daily, 27%
for three times daily and 6% for four times daily. Further-
more, the authors examined the relationship between
adherence and treatment efficacy and found that adher-
ent patients had an 89% chance of maintaining remission
in comparison to patients who were non-adherent (39%).
With respect to the two medications in this study, Meza-
vant is dosed once daily whereas Asacol is dosed three
times daily for acute treatment and two times daily for
maintenance. Therefore, it might be assumed that the
difference between the remission rates of Mezavant and
Asacol might have been even higher if adherence were
considered within the model.
In addition, it is indicated that UC-patients have an
increased risk of developing colorectal cancer (CRC).
This risk, however, may be reduced by the adherent use
of 5-ASA [30-32]. Therefore, the inclusion of the
increased risk of CRC due to non-adherence might also
have as well increased the cost effectiveness of Mezavant
in comparison to Asacol.
Further uncertainty is connected to the inclusion of sur-
gery associated mortality data from the UK, which medical
system is not directly comparable to the German system.
However, due to the lack of sufficient German data, it
seemed reasonable to include data from another developed
European country. Furthermore, the percentage of patients
in hospital who needed to undergo a surgery was taken
from the German Federal Statistical Office (10.9%). How-
ever, this figure refers to the overall risk of surgery in
hospital for all UC-patients and is not specific for the UC-
population we are focusing on. Therefore, we have
checked the importance of this figure by conducting a
one-way sensitivity analysis (variation: 5-30%). The results
change only slightly (incremental costs over a 5-year-per-
iod +/- 20 Euro). This shows that this specific figure has
not a great impact on the results of this model.
Further uncertainties are connected to the structure of
the model. Treatment for frequently relapsing patients can
include oral immunosuppressants or TNF-alpha-inhibiting
agents which were not included in the model. However,
TNF do not play an important role in the treatment of
UC-patients in Germany yet [21]; furthermore, there is no
valid data with respect to transition probabilities which
could have been included in the model. The inclusion of
TNF therapy would probably not have an effect on the
original aim of the study (comparison of Asacol and Meza-
vant) because the population receiving such therapy is very
small and both drugs were given the same treatment path-
ways in the model. Further uncertainty is connected with
assumption that patients who suffer a severe relapse/mesa-
lazine failure need hospitalization. On the other hand,
Table 3 Summary of the base case analysis
Intervention Estimated
5-year costs
QALY gained Difference (cost) Difference (QALY) Cost per QALY
deterministic Mezavant 4,940 € 3.320 -624 € 0.011 NA
Asacol 5,564 € 3.309
probabilistic Mezavant 4,939 € 3.320 -705 € 0.022 NA
Asacol 5,644 € 3.330
Figure 2 Scatter plot of PSA analysis. QALY: quality adjusted life
year.
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some patients may also require an immediate surgery due
to a severe relapse. However, no valid data exists for a
more precise approach and the model structure includes
no surgical or post-surgical complications. Nevertheless,
post-surgical complications could likely occur in patients
with a long active disease history. Due to lack of robust
data with respect to further health states and transition
probabilities, the model was not designed to assess post-
surgical complications. Thus, only robust and conservative
transition probabilities were included into the model
calculations.
The resource use and costs which were included in the
model are also connected with some uncertainties. The
data source used for collection of resource usage and
costs [21] is not set as a longitudinal collection of data
but on a cross-sectional study design and therefore repre-
sents rather a snapshot at a specific time point. However,
the study is the most eligible one in the German context
as it includes inpatient as well as outpatient resource use,
is up to date (2007) and addresses the perspective of the
SHI. According to the current German guidelines [22]
the drug prices of Mezavant and Asacol were taken from
July 2009. To check whether the prices have changed
after July 2009 or at the beginning of 2010 (and thereby
the relative results of the analysis), the SHI-drug prices
were re-calculated using current drug price. The last
price change occurred in April 2010. After subtracting
discounts and co-payments by patients, the drugs price
of Asacol is currently 0.39 Euro per 400 mg and 1.00
Euro per 1,200 mg of Mezavant [23]. Hence, Mezavant
still is less costly for the SHI than Asacol. If these new
prices were put into the model, the results would have
even been more favorable to Mezavant. In general, due to
the specialty of the reimbursement system in Germany,
the results of this cost-effectiveness-model are not
directly transferable to other foreign settings.
There is an urgent need for more research regarding
the health care of patients suffering from UC. As stated
above, long-term data which gives information on the
long-term effects of specific UC-therapies are missing to
date. Therefore, in models efficacy data from clinical
trials needs to be extrapolated which is associated with
uncertainties. Furthermore, utility data for UC-patients
is very rare. The only utilities which were eligible for
this cost effectiveness model came from two studies that
were only available in an abstract format [19,20]. There-
fore, there is an urgent need to collect utility data for
patients with UC, also for different country settings.
To our knowledge, there exists no cost effectiveness
model for the German setting yet, which compares
mesalazines in the treatment of UC. Hence, it is not
possible to compare the results of this study with other
German publications. This indicates a need for further
health economic research in this area to identify cost
effective options in the treatment of UC-patients in
Germany.
In summary, the analysis shows that over a five year as
well as a lifelong time horizon, Mezavant is less expen-
sive and results in higher gains of QALYs compared
with Asacol. The analysis and its results are reasonably
robust as the PSA shows.
Conclusions
The analysis suggests that patients treated with Meza-
vant are in remission longer, gain more QALYs, and
incur lower direct costs to the SHI compared with
patients receiving Asacol. Mezavant may therefore be a
suitable first-line option for the induction and mainte-
nance of remission in UC.
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NA: not applicable; PSA: probabilistic sensitivity analysis; QALY: Quality
adjusted life years; SHI: Statutory health insurance; UC: ulcerative colitis.
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